武田与Biological E. Limited合作加快登革热疫苗在流行地区的普及速度-动脉橙

武田与Biological E. Limited合作加快登革热疫苗在流行地区的普及速度

2024-02-27 seekingalpha 等7家媒体报道商业合作





武田和Biological E.Limited宣布建立合作伙伴关系，以加速获得登革热疫苗QDENGA®。该伙伴关系旨在到2030年将疫苗提供给流行国家的政府，支持国家免疫计划。MDV提供成本和物流效益。BE将把生产能力提高到每年5000万剂，帮助武田在十年内达到1亿剂的目标。这是基于武田现有的制造能力以及与IDT Biologika GmbH的合作关系。该合作关系预计将对公共卫生产生重大影响。（摘要由动脉网AI生成）

关联公司

 TakedaBiologicalE.Limited

2024-02-27 Takeda and India's Biological E. to accelerate access to dengue vaccine in endemic areas

seekingalpha
2024-02-27 Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

businesswire
2024-02-27 Takeda Signs Manufacturing Partnership With India's Biological E. For Dengue Vaccine QDENGA

RTTNews
2024-02-27 Takeda, Biological E enter manufacturing pact to produce 50 million doses of Dengue vaccine

economictimes.indiatimes
2024-02-27 Takeda and Biological E. Limited Collaborate to Expedite Dengue Vaccine Availability in Endemic Areas

PHARMA FOCUS ASIA
2024-02-27 Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

BioSpace